The clinical behavior of prostate cancer is extraordinarily heterogeneous. For example, a significant proportion of prostate cancers have limited propensity for metastasis and can be safely managed without any local or systemic treatment. 1, 2 On the other hand, prostate cancer remains a leading cause of death for men worldwide due to a minority of prostate cancers that exhibit a lethal phenotype, with eventual evolution to a disease state that is refractory to all known treatments despite aggressive therapy. 3, 4 In order to identify where along this spectrum a given prostate cancer is likely to exist, risk stratification systems, based primarily on clinical and pathologic factors, have been developed.
The National Comprehensive Cancer Network (NCCN)-risk stratification system is one of the most commonly employed prostate cancer-risk stratification tools. 5 The NCCN system uses clinical tumor stage, biopsy ISUP grade group, 6 and pretreatment PSA to stratify patients into risk groups. Although the discriminatory ability of this classification has been validated in numerous studies, there remains substantial heterogeneity of outcomes within each risk group, especially for high-risk patients. 3, 7, 8 Therefore, several modifications have been proposed. 3, 7, 8 The NCCN is now incorporating a substratification of high-risk current used as a factor to distinguish favorable from unfavorable intermediate risk. 9 Furthermore, the absolute number of cores with
Gleason score ≥ 8 is highly dependent on the number of cores taken, whereas PPBC, being a relative measure, is independent of the number of cores taken, assuming oversampling of suspicious areas in not performed. Lastly, PPBC was available in our database, whereas absolute number of ISUP grade group 4-5 cores was not.
Patients were followed to determine clinical endpoints after surgery.
PSA recurrence-free survival (PSA-RFS) was defined as a single PSA greater than 0.2 ng/mL, two values of 0.2 ng/mL, or secondary treatment for an elevated postoperative PSA. Development of distance metastases (DM) was determined by bone scans or other imaging. Prostate cancer-specific mortality (PCSM) was defined as having metastatic progressive CRPC at time of death with no obvious indication of another cause of death. Allcause mortality (ACM) was determined from the medical records.
| Statistical analysis
Characteristics of VHR patients versus all others were compared using t-tests or rank sum tests for continuous variables and chi-squared tests for categorical variables. The association between risk group (low-risk, FIR, UIR, SHR, VHR) and the clinical endpoints (PSA-RFS, DM, ACM) was tested using Cox proportional hazards models. Competing risks models were used to test the association between risk group and PCSM, with non-prostate cancer death as the competing risk.
Multivariable models were adjusted for age, race, year of surgery, and surgical center. Analyses were repeated changing the reference risk group to compare patients with SHR to those with UIR and VHR.
Then, men with UIR and SHR were combined into one group and compared to those with low-risk or FIR, and men with VHR were also compared to those with low-risk or FIR. Cumulative incidence curves were plotted for the five risk groups and each of the clinical endpoints. A new stratification system was created by combining groups with similar risk. C-indices were compared between our new risk grouping and the standard three-tiered NCCN-risk groups.
Statistical significance was defined as P < 0.05. All analyses were performed using Stata v14.0.
| RESULTS
Baseline characteristics are summarized in Table 1 . Median follow-up for the entire cohort from date of prostatectomy was 78 months (IQR: We compared PSA-RFS, DM, PCSM, and ACM rates for patients with low risk, FIR, UIR, SHR, and VHR disease ( Figure 1 and Table 2 ).
Compared to patients with low-risk disease, those with VHR cancers had markedly higher rates of PSA-RFS (adjusted hazard ratio Table S1 ). None of these groups had significantly different overall survival.
Given the similar outcomes for SHR and UIR patients, we create a four-tiered risk stratification system: Group 1 (low risk), Group 2 (FIR), Group 3 (UIR and SHR), and Group 4 (VHR) (Figure 2 ). These groups had significantly different PSA-RFS, DM, and PCSM (Table 4 ). For 
| DISCUSSION
In this study, we validated that high-risk prostate cancer is a heterogeneous disease that can be dichotomized into SHR and VHR groups based on primary Gleason pattern, PPBC, and number of NCCN high-risk features. These criteria, which are similar to the system now recommended by NCCN guidelines, 3 identify distinct clinical entities with disparate outcomes following prostatectomy. After adjustment for other factors in multivariable analysis, VHR patients were 2.4 times as likely to experience DM and 3.2 times as likely to die from prostate cancer as those with SHR disease. We note that these differences were observed despite the fact that patients with VHR disease in this study were selected to undergo surgery, and thus probably were more likely to have organ-confined disease, lower tumor bulk, lower comorbidity, and younger age than those VHR patients undergoing radiation and androgen deprivation. Overall, nearly 70% of VHR experienced PSA relapse within 10 years of prostatectomy, with 16% experiencing DM and 11% having PCSM during this time period. However, it is important to note that the median follow-up for the VHR cohort was 78 months, and increased prostate cancer related recurrences and deaths are likely with longer follow-up.
We also observed that SHR patients not meeting VHR criteria had no difference in PSA-RFS, DM, PCSM, or OS when compared to those with UIR disease. Given that SHR patients are much more similar to UIR patients than VHR patients, we propose modifying current NCCN criteria not only to separate high-risk disease into SHR and VHR groups, as is currently allowed, but also combining UIR and SHR patients into a single risk group.
Our results are remarkably consistent with a recent study of prostate cancer patients undergoing dose-escalated radiation therapy (RT) with or without androgen deprivation therapy at a high-volume academic institution. 13 As in this study, VHR patients were found to have dramatically worse outcomes following RT in comparison to SHR patients. Additionally, SHR and UIR patients undergoing RT had identical clinical outcomes, similar to what was observed in our surgical cohort. The consistency of these findings across independent datasets from disparate practice settings and using different treatment paradigms provides strong support that these results may be broadly applicable to patients with localized prostate cancer, and provides independent validation of our results.
These results have important potential implications for therapeutic recommendations. Given the similar outcomes for UIR and SHR prostate cancer following prostatectomy, it is likely that these patients will benefit from similar therapeutic paradigms. This may mean that a proportion of high-risk patients are able to undergo risk Across cancer types, the majority of the most aggressive malignancies require a combination of surgery, radiation, and systemic therapy to maximize the likelihood of cure. Extrapolating from this paradigm to VHR prostate cancer, these patients may derive benefit from multi-modality approaches that combine radical prostatectomy with adjuvant radiotherapy and concomitant androgen deprivation.
However, optimal management of SHR and VHR remains speculative, because few randomized studies incorporating surgery have been conducted in these patients. Prospective evaluation of therapeutic paradigms for SHR and VHR patients, especially those incorporating radical prostatectomy, is warranted.
We note that our VHR criteria differed slightly from those endorsed by the NCCN, first proposed by investigators from Johns
Hopkins after a systematic evaluation of prognostic factors. First, no patients in our study had clinical invasion of the seminal vesicle, rectum, or bladder, which are considered very high-risk criteria.
Secondly, instead of using five or more cores of ISUP grade group 4-5 disease as a criterion for VHR classification, we chose to PPBC greater than 50% as a VHR feature, given that this number was readily available in our database and PPBC has been repeatedly validated as an important predictor of outcome in multiple independent datasets. 9, 11, 12 Furthermore, the absolute number of cores with Gleason score ≥ 8 is highly dependent on the number of cores taken, whereas PPBC, being a relative measure, is independent of the number of cores taken, assuming oversampling of suspicious areas in not performed. It is notable that approximately 75% of VHR patients in our study were classified as VHR due to PPBC ≥ 50%, likely as a result of patients with other aggressive features being preferentially treated with androgen deprivation and radiation at the institutions contributing to our database. Although this limits to a certain degree the comparison of our results to previous studies that used biopsies with greater than four cores of Gleason 8-10 prostate cancer to define VHR disease, 3 the hazard ratios we report for DM (HR = 2.4) and PCSM (HR = 3.2) when comparing the VHR and SHR groups in this study are similar to those given that both identify high-risk patients with high-volume prostate cancer. However, at institutions that extensively use MRI-guided biopsy with oversampling suspicious areas on imaging, and the utility of PPBC or absolute number of high grade cores may be reduced given that it no longer provides as accurate a measure of overall tumor volume, and alternate metrics may be necessary.
Our study has several limitations that warrant further discussion. Additionally, the use and timing of salvage therapy, which is known to impact DM and PCSM, 18 was not accounted for in our analysis.
Nevertheless, we believe our study has several strengths, such as a relatively uniform treatment paradigm, excluding patients receiving androgen deprivation or adjuvant radiotherapy, a relatively large cohort, and a multi-institutional setting including numerous urologists, and we think that the results are robust despite their inherent limitations, especially in combination with similar reported results from patients undergoing radiotherapy. 13 In summary, we have demonstrated that high-risk prostate cancer is highly heterogeneous, and that primary Gleason pattern, number of positive biopsies cores, and number of NCCN high-risk factors play an integral role in distinguishing those at highest risk for adverse outcomes following prostatectomy. Moreover, high-risk patients not meeting VHR criteria have identical prognosis to those with UIR disease, and we therefore suggest combining these groups both for prognostic and therapeutic purposes. Further advancements in risk stratification using novel imaging, genomic, proteomic, and novel molecular biomarkers, will hopefully continue to improve our ability to risk stratify these patients in the future.
